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1
METHODS AND PHARMACEUTICAL
COMPOSITIONS FOR DECORPORATION OF
RADIOACTIVE COMPOUNDS

This application claims the bene?t of US. provisional
patent application Ser. No. 60/983,401 ?led on 29 Oct. 2007.
This invention Was made With at least partial Government
support under National Institutes of Health Award No.
HHSN266200500045C. The Government may have certain

rights in this invention.
Where RihORl or iNHRz;
Rl:same or different and is independently selected from

TECHNICAL FIELD

H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or benZyl

The present invention relates generally to chelating agents
and to related methods for utilizing those chelating agents in

and at least one R1 is not hydrogen; and
R2:same or different and is independently selected from

pharmaceutical compositions to decorporate or remove tran
suranic or other radioactive elements and compounds, from
mammals such as humans.

Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or phe
20

BACKGROUND OF THE INVENTION

The calcium and Zinc salts of diethylenetriamine penta

25

acetate (Ca-DTPA and Zn-DTPA) have been approved by the
Food and Drug Administration for the decoporation, removal

The method may further include administering the decor
poration agent for an extended period of time such as over

of humans With the transuranic metals (Z>92), plutonium,
30

In accordance With an additional aspect of the present

onto radioactive materials or certain other poisons that enter
the body. Once bound to the radioactive material or poison,

and or feces. The chelating agents help decrease the amount
of time it takes to get the poison out of the body.

days and Weeks in order to achieve medically su?icient deco

rporation.

DTPA are chelating agents that Work by binding and holding
the chelating agent is then passed from the body in the urine

includes administering preferably betWeen about 5 and about
250 milligrams of decorporation agent per kilogram of the
total Weight of the mammal per day. More preferably, the dose
is betWeen 5 to 100 milligrams/kg body Weight, and most
preferably the dose is between 15 to 45 milligrams/kg body

Weight.

or elimination of knoWn or suspected internal contamination

americium and curium. More speci?cally Ca-DTPA and Zn

nylalanine ethyl ester.
More speci?cally describing the invention, the method

invention a method is provided for treating a mammal to
35

Ca-DTPA and Zn-DTPA are not absorbed from the GI tract

remove radioactive elements and compounds comprising the
step of administering to the mammal a pharmaceutically
effective amount of a pharmaceutical composition including
a pharmaceutical carrier and a decorporation agent having a
chemical formula

to any appreciable extent and therefore must be administered

by (l) subcutaneous injection directly into a vein, (2) intra

40

venously by dripping into a vein from a bag or (3) by nebu
liZed inhalation by means of a mist or spray breathed into the

lungs.
A need exists for the development of a form of diethylene
triamine penta-acetic acid (DTPA) that can be administered

45

orally for use in the possible event of a massive radiation
poisoning emergency such as could occur by the detonation
of a dirty bomb by terrorists or inadvertent release of radio
activity into a Work place or the environment. The present

invention relates to pharmaceutical compositions and treat
ment methods meeting this need. More speci?cally, esters
and amides of DTPA have been developed that are readily
absorbed folloWing oral administration and are subsequently
and rapidly hydrolyZed back to active DTPA by esterases or
amidases normally present in the intestinal lumen, liver and/

0

50

Where RihORl or iNHRz;
Rl:same or different and is independently selected from

H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or benZyl
55

or blood.

and at least one R1 is not hydrogen; and
R2:same or different and is independently selected from

Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or phe
nylalanine ethyl ester.

SUMMARY OF THE INVENTION
60

enhancing agent, and a sWeetening agent as desired depend

In accordance With the purposes of the present invention as
described herein, a method is provided for treating a mammal

ing upon the form of the product (eg. liquid dosage forms and
solid dosage forms such as poWder, pill, tablet, capsule, gel

to remove systemic transuranic or other radioactive elements

and compounds. The method is broadly described as com

prising the step of administrating to the mammal a pharma
ceutically effective amount of a decorporation agent having a
chemical formula

The pharmaceutical composition may further include an
antioxidant, a preservative and/or a binder, a viscosity

65

cap for oral administration).
In accordance With yet another aspect of the present inven
tion a composition is provided for removing systemic radio
active compounds from a mammal. The composition com

US 8,030,358 B2
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4

prises a pharmaceutical carrier and a pharmaceutically
effective amount of a decorporation agent having a chemical
formula

cose, gelatin, acacia, sucrose, dextrin, guar gum, hydroxy

ethyl cellulose, polymethacrylates, maltodextrin, povidone,
Zein, methyl cellulose, and sodium alginate. It is Well knoWn
that other compounds not listed can serve as binders and these

0

compounds are not intentionally omitted herein.
Further the composition may include the mixture of the

O

liquid, semi-liquid or crystalline decorporation agent With an
additive in order to aid in the preparation of an acceptable

O HLR R)“ O

pharmaceutical composition. For example, a liquid or semi
liquid decorporation agent may be added to a dry and porous
pharmaceutical excipient such as colloidal silicon dioxide
that absorbs the liquid in order to impart ?oW properties
similar to the pharmaceutical excipient. Other examples of
excipient include, but are not limited to, bentonite, cellulose,
kaolin, and magnesium aluminum silicate. As another
example, a crystalline decorporation agent may be added to

RJ\/N\/\N/\/N\)kR
R

of

dry pharmaceutical excipient to disperse the agent and
improve ?oW. Examples of such excipients include, but are
not limited to, lactose, mannitol, maltodextrin, and silicon

Where R*\ORl or iNHRZ;
RIIsame or different and is independently selected from

H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or benZyl
and at least one R1 is not hydrogen; and
R2:same or different and is independently selected from

20

and about 30 Weight percent disintegrant. The disintegrant
may be selected from a group consisting of alginic acid,

Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or phe

crospovidone, croscarmellose sodium, soy polysaccharides,
cellulose, magnesium aluminum silicate, povidone, sodium

nylalanine ethyl ester.
For oral administration, the carrier may be a solution com

prised of a mixture of solvents including, but not limited to,

25

In the folloWing description there is shoWn and described

propylene glycol, sesame oil, soybean oil, or triacetin. The
30

of agents including, but not limited to, acacia, alcohols, alg

preferred embodiments of the invention, simply by Way of
illustration of some of the modes best suited to carry out the

invention. As it Will be realiZed, the invention is capable of

inic acid, carbomer, carboxymethylcellulose, ethylcellulose,

other different embodiments and its several details are

povidone, or xanthum gum. The pH of the vehicle can also be

adjusted to a pH that best stabiliZes the decorporation agent.
The preferred pH is in the range of pH 2-8 While the pH range

starch glycolate and sodium carboxymethyl starch. It is Well
knoWn that other compounds not listed can have disintegrant
properties and these compounds are not intentionally omitted
herein.

Water, ethanol, propylene glycol, glycerin, comoil, ethyl ole
ate, glycofurol, mineral oil, peanut oil, polyethylene glycol,
viscosity of the vehicle can also be increased With any number

dioxide.
Further the composition may include betWeen about 0.01

capable of modi?cation in various, obvious aspects all With
out departing from the invention. Accordingly, the draWings
35

of 3-7.5 is more preferred, and the pH range of 3.5 to 7 is most

and descriptions Will be regarded as illustrative in nature and
not as restrictive.

preferred. pH adjusting agents include, but are not limited to,
citric acid/citrate, phosphoric acid/phosphate, or boric acid/
borate.
The composition for an oral solution includes betWeen

BRIEF DESCRIPTION OF THE DRAWINGS
40

about 50 and about 98 Weight percent pharmaceutical carrier
With the decorporation agent in the pharmaceutical carrier at

equivalent molar dose of decorporation agent of the present

a concentration ranging from 5 to 250 mg/mL, and more

invention orally administered to a rat in a 10% ethanol solu

preferably at a concentration ranging from 50 to 150 mg/mL.
The composition may further include betWeen 0.001 and
about 3 Weight percent antioxidant. The antioxidant may be
selected from a group consisting of ascorbic acid, its salts and
esters; fumaric acid, its salts and esters; malic acid, its salt and
esters; alpha-tocopherol, its salts and esters; sodium met

abisulphite, sodium bisul?te; butylated hydroxyanisole
(BHA); butylated hydroxytoluene (BHT); gallic acid, its salts

FIG. 1 graphically illustrates the bio-availability of 5 mg of
DTPA administered to rats intravenously; and
FIG. 2 graphically illustrates the bioavailability of an

tion.
DETAILED DESCRIPTION OF THE PREFERRED
EMBODIMENTS OF THE INVENTION

A composition for removing radioactive elements and
50

compounds, such as transuranic compounds, from a mam

mal, such as a human, comprises a pharmaceutical carrier and
a pharmaceutically effective amount of a decorporation agent
having a chemical formula

and esters; EDTA. It is Well knoWn that other compounds not
listed can have antioxidant properties and these compounds
are not intentionally omitted herein.

The composition may further include betWeen about 0.001

55

and about 10 Weight percent preservative. That preservative

O

O

may be selected from a group consisting of methylparaben,

ethylparaben, propylparaben, butylparaben, benZoic acid,
sodium benZoate, benZyl alcohol, sorbic acid and potassium

sorbate, EDTA, glycerol, phenol, thimerosol, phenoxyetha

60

nol, and cresol. It is Well knoWn that other compounds not
listed can have preservative properties and these compounds

lose, silicon dioxide, dibasic calcium phosphate, starch, glu

RAK/NWN/VNQkR
R

are not intentionally omitted herein.

Further the composition may include betWeen about 0.01
and about 25 Weight percent binder. The binder may be
selected from a group consisting of microcrystalline cellu

O %R R)“ O

65
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Where R*\ORl or iNHRZ;
RIIsame or different and is independently selected from

solutions or suspensions in aqueous or non-aqueous liquids,
or as oil-in-Water or Water-in-oil emulsions, or as micelles,

H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or benZyl

nanoparticles, liposomes, or microparticles. For example, the

and at least one R1 is not hydrogen; and
R2Isame or different and is independently selected from

formulation may include a viscosity-enhancing agent such as

beesWax, other Waxes, polymer, glycerolmonooleate, leci
thin, PEG 400 Monostearate, hydroxy propyl cellulose,

Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or phe

hydroxy propyl methyl cellulose, polyethylene glycol 8000
(PEG 8000), PEG 3350, methyl cellulose, 2-propenoic acid
(Carbopol 934P), polysorbate 20 (TWeen 20), polysorbate 80
(TWeen 80) and alpha-Tocopheryl polyethylene glycol 1000

nylalanine ethyl ester.
The phrase “pharmaceutical carrier” as used herein means
a pharmaceutically-acceptable material, composition or
vehicle, such as a liquid or solid ?ller, diluent, excipient,

solvent or encapsulating material, involved in carrying and

succinate (TPGS) and mixtures thereof. The formulation is
heated and then ?lled into hard gelatin capsules. Upon cool

transporting an active agent, in this case the decorporation
agent, from one organ or portion of a subjects body to another

ing, the capsules Would contain a semi-solid material that

included the decorporation agent.

organ, or portion of the subjects body. Some examples of
materials that can serve as pharmaceutical carriers include:

Formulations suitable for sub-lingual or bucal administra

poWdered cellulose, calcium carbonate, lactose, starch, poly
lactic acid, polyglycolic acid, phospholipids, mannitol, cal
cium sulfate, sorbitol, dicalcium phosphate, kaolin, sodium
chloride, poWdered sugar and microcrystalline cellulose.

tion include loZenges, rapidly dissolving tablets, thin-?lms,
lollipops comprising the decorporation agent and, typically a
20

The phrase “pharmaceutically effective amount” as used
herein means that amount of decorporation agent Which is

effective for removing systemic transuranic compounds from
a mammal or for producing some other desired therapeutic
effect in a mammal in accordance With a reasonable bene?t/

25

risk ratio applicable to any medical treatment.

The phrase “medically su?icient decorporation” relates to

soybean oil and (2) medium-chain triglycerides such as min
30

Self-emulsifying drug delivery systems are mixtures of

absorption of highly lipophilic compounds. They can be for

that When administered over time removes detectable amount

continue until the transuranic compound is no longer detect
able by the various modes of elimination from the body.
Antioxidants useful in the present invention include but are
not limited to ascorbic acid, its salts and esters; fumaric acid,
its salts and esters; malic acid, its salt and esters; alpha

35

emulsi?cation, self-emulsifying drug delivery systems con
40

solubiliZed phase of the drug, thereby increasing absorption

potential.
Formulations of the invention may be prepared by any
45

ture into the desired shape. For example, a tablet may be

prepared by compressing an intimate mixture comprising a
50

Binders useful in the present invention include but are not

limited to microcrystalline cellulose, dibasic calcium phos
55

Possible formulations include those suitable for oral, sub
istration. Most suitable means for administration for a par
60

transuranic poisoning, the length of time betWeen the poison
ing and the discovery of the poisoning and, obviously, the age
and condition of the patient.

liquid dilutant. In addition, a solution or suspension of the
decorporation agent may be ?lled into a solid dose form such
as a hard-gelatin capsule or soft-gelatin capsule.
In addition to the ingredients mentioned above, formula
tions to the present invention may include other additives
knoWn to those skilled in the art of pharmacy to be useful for
their intended purpose. For example, formulations suitable

for oral administration may include ?avoring agents.
The method of treating a mammal to remove radioactive
elements or compounds such as systemic transuramic com

Formulations suitable for oral administration may be pro

amount of the decorporation agent: as poWders or granules, as

poWder or granules of the decorporation agent and one or
more optional ingredients such as a binder, lubricant, inert
dilutant or surface active dispersing agent, or by molding an

intimate mixture of poWdered decorporation agent and inert

lingual, buccal, nasal, pulmonary, rectal, and topical admin

vided as discreet units, such as tablets, capsules, cheWing
gum, loZenges or the like, Which containing a predetermined

suitable method, typically by uniformly and intimately
admixing the decorporation agent and carrier in the required
proportions and then, if necessary shaping the resulting mix

not limited to methylparaben, ethylparaben, propylparaben,

ticular patient Will depend on the nature and severity of the

tain exogenous surfactants to self-promote micelle forma
tion. The emulsi?cation increases the surface area of the

EDTA.
Preservatives useful in the present invention include but are

phate, starch, glucose, gelatin, acacia, sucrose, dextrin, guar
gum, hydroxyethyl cellulose, polymethacrylates, maltodex
trin, povidone, Zein, methyl cellulose, and sodium alginate.

neously self-emulsify upon ingestion after dilution by the
aqueous ?uids of the GI tract. Unlike a non-emulsion formu

sodium bisul?te; butylated hydroxyanisole (BHA); butylated

butylparaben, benZoic acid, sodium benZoate, benZyl alcohol,
sorbic acid and potassium sorbate, EDTA, glycerol, phenol,
thimerosol, phenoxyethanol, and cresol.

mulated as microemulsion pre-concentrates that Will sponta

lation that relies on endogenous surfactants (i.e. bile salts) for

tocopherol, its salts and esters; sodium metabisulphite,

hydroxytoluene (BHT); gallic acid, its salts and esters;

eral oil.

oils, surfactants and solvents that can improve the oral

poisonous and radiotoxic in the body. A decorporation agent
of the transuranic compound from the body Will generally
improve the medical condition of the mammal. Thus, it is
envisioned that dosing of the decorporation agent should

Formulations particularly useful for pediatric administra
tion include oil solutions and self-emulsifying drug delivery
systems. A simple oil-based solution contains dissolved
decorporation agent. Various oils may be utiliZed including
pharmaceutical grade vegetable oils such as (l) long-chain
triglycerides such as corn oil, cottonseed oil, sesame oil and

the administration of the decorporation agent to a mammal to
result in detectable elimination of the radioactive element

and/ or compound from the mammal in the urine, feces, other
bodily ?uids and exhaled gas from the lungs. It is appreciated
by those in the ?eld that the transuranic compounds are very

?avored base, such as sugar and acacia or tragacanth in pas
tilles comprising the active compound in an inert base, such as
gelatin and glycerin or sucrose acacia.

65

pounds may be broadly described as comprising administer
ing to the mammal a pharmaceutically effective amount of a

decorporation agent having a chemical formula

US 8,030,358 B2
8

7
Prodrug Synthesis
O

O

Target molecules preparation summary: DTPA esters may
be prepared using DTPA as a starting material. The starting

O %R R)% O

material diethylenetriaminepentaacetic acid, (DTPT, 1) could

RAK/NWN/VNQkR
R

be smoothly converted to the pentaethyl ester 2, (C2E5) in

high yield by re?uxing the pentaacid in ethanol acidi?ed With
HCl gas, aqueous HCl, sulfuric acid, etc, etc. Removal of the

f

solvent yielded the hydrochloride salt of:

Where R*\ORl or iNHRZ;
RIIsame or different and is independently selected from

OR

H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or benZyl

RO

and at least one R1 is not hydrogen; and
R2:same or different and is independently selected from

Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or phe
nylalanine ethyl ester.
Alternatively, the method may be described as comprising
administrating to the mammal a pharmaceutically effective
dosage amount of a pharmaceutical composition including a

N

j‘/\N/\/ \/\N/\’(

OR

o KH/OR ROW‘) 0

20

O

O

2. R : Ethyl

pharmaceutical excipient and a decorporation agent having a
chemical formula

25

as a glassy, hygroscopic solid. We also prepared the free base
as a clear, colorless oil by Washing With an aqueous sodium

carbonate solution, drying the organic layer With sodium
0

o

sulfate and removal of the volatiles. The corresponding Cl8

pentaester:

o %R 11% o

30

Rk/N\/\N/\/N\)i\R
R
35

0

Where R*\ORl or iNHRZ;
RIIsame or different and is independently selected from

40

O

H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or benZyl

O

and at least one R1 is not hydrogen; and
R2:same or different and is independently selected from

R I octadecyl

Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or phe
nylalanine ethyl ester. Either oral or nasal administration may
be utiliZed.
The method includes administering betWeen about 5 and
about 250 milligrams and more typically betWeen about 15

and about 45 milligrams of decorporation, agent per kilogram
of the mammal’s total body Weight per day. Further the
method includes administering the decorporation agent for at

45

Was prepared by heating DTPA in toluene in an excess of
l-pentadecanol in the presence of sulfuric acid With aZeotro
pic removal of Water. Column chromatography to remove the
excess alcohol provided the above compound as a Waxy solid.
We prepared the C 12 pentaester:

50

least one day and, if needed, over an extended period of time

O

such as over days and Weeks.

The folloWing synthesis and examples are presented to
further illustrate the invention, but it is not to be considered as

limited thereto. The nomenclature system for the substituted
DTPA compounds is as folloWs:
Abbreviation

OC12H25

55

C12H25O

N

WNA/ \/\NW
0

Compound

ocuH25

o

OC12H25

60

C2E5
Cl2E5
C18E5

ethyl ester, penta-substituted
lauryl ester, penta-substituted
stearyl ester, penta-substituted

CbMZyIES

benzyl ester, penta-substituted

CPhmA5

amide of phenylalanine ethyl
ester, penta-substituted

OC12H25

O

O

by a different route. Dodecylbromo acetate Was prepared
65

cleanly from l-dodecanol and bromo acetyl bromide. The
bromoacetate Was reacted With diethylenetriamine to yield,
after column chromatography, the C12E5 as an orange oil.

US 8,030,358 B2
9

10

DTPA DerivatiZation

diethylenetriamine to produce the requisite pentaester Which
Was puri?ed by column chromatography.

_

_

The triester series Was approached by ?rst reacting dieth

Attennon Was next turned to the PreParanOn of DTPA
ylenetriamine With ethyl tri?uoroacetate in dichloromethane
esters by the alternate Pathway Shown 1n Scheme 2~ The 5 to produce the ditri?uoroacetamide 9 in good yield. Further
Carbon Skeleton Of DTPA Can be prepared by reaction of
reaction With 3 equivalents of ethyl bromoacetate and a base

bromoacetic acid derivatives. The pentadodecyl ester C12E5
Was prepared by reaction of dodecylbromoacetate 7 With

provided the triethyl ester 10, and using 1 equivalent of ethyl
bromoacetate, the monoester ll.

O

O

OH

HO

OH

N

OH

N/\/ \/\N/X
o

A020, Py

HO

N

—DiOXan6
,
70 deg C.

o O

O

N/\/ \/\N

8 hr

0

o

O
OH

OH

O

O

1

4
EtOH
HCl
O

2. R I Ethyl
3. R I octadecyl

5

O

O

N

H2N/\/ \/\NH2 +

BIQK

OC12H25

/

C12H25

—>

c H o

N

00 H

12 25 WNA/ \/\N
o

12 25

oclzH25

o

OC12H25
6

7

O

O
O

O

O

O

O
H

i /\/N\/\

F3C

8

H

Br

H

0P3

OEt

NH
a

o
F3C
EtO

OEt
N/\/

N\/\ /\
N

iPrZNEt
C133
OEt

o
F3C

OEt 0

N

L

C133

US 8,030,358 B2
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EXPERIMENTAL EXAMPLES

mL). The reaction Was alloWed to stir 2 h then bromoethylac
etate (99.0 g, 0.595 mol) added, and the reaction Warmed to
room temperature overnight. The reaction Was diluted With

DTPA Pentaethyl Ester (C2E5), 2

aqueous sodium bicarbonate, and extracted With ethyl

DTPA (5 g, 12.7 mmol) Was suspended in anhydrous abso
lute ethanol (200 mL) that had been saturated With anhydrous

acetate, Which Was back extracted With brine. The organic
layer Was dried, and the volatiles removed to produce an oily

HCl. The reaction Was stirred at re?ux overnight under an

glass. MS (MALDI) 554 (M+1).

Argon atmosphere. Approximately 20 mL of ethanol Was

Monoethyl Ester 11.

distilled, and the reaction kept at re?ux a further 24 h. The
volatiles Were removed in vacuo and a glassy, hygroscopic

The di-tri?uoroacetamide 9 (55 g, 0.186 mol) Was dis

solved in anhydrous acetonitrile (300 mL), and diisopropyl
ethylamine (28.9 g, 0.223 mol) added. Ethylbromoacetate

solid Was obtained in quantitative yield (7.2 g). To prepare the
free base, the material Was dissolved in dichloromethane and

(37.4 g, 0.223 mol) Was added dropWise to the solution and

Washed With 5% aqueous potassium carbonate, dried With

then it Was stirred overnight at room temperature. The reac

NaZSO4 and concentrated in vacuo to yield a clear, colorless

tion Was diluted With aqueous sodium bicarbonate, and
extracted With ethyl acetate, Which Was back extracted With

oil. Mass spectrum (M+1) El, 534. lH-NMR (CDCl3) 4.16 (q,

1:7 HZ, 10H); 3.58, (s, 8H), 3.48, (s, 2H), 2.86-2.80 (complex
multiplet, 8H), 1.27 (t, 1:7 HZ, 12H), 1.26 (t 1:7 HZ, 3H).
DTPA Penta Cl8 Ester (C18E5), 2
DTPA (5.0 g, 12.7 mmol) Was suspended in toluene and 3
mL concentrated sulfuric acid added. Octadecyl alcohol (31

brine. The organic layer Was dried, and the volatiles removed

to produce an oily glass. MS (MALDI) 382 (M+1).

Prodrug Synthesis
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g, 114 mmol) Was added and the reaction ?tted With a Dean

amine, 6. The primary amines could be selectively protected
as the di-tri?uoroacetamide by reaction With ethyl tri?uoro
acetate to produce 9 in good yield. Reaction of 9 With 3

Stark apparatus. The reaction Was re?uxed overnight Where
upon the volatiles removed. The crude material Was dissolved

in dichloromethane and separated by column chromatogra
phy (silica gel) eluting With dichloromethane and then 20%

Various esters of DTPA Were prepared from diethylenetri

equivalents of ethylbromoacetate and NaH produced the tri
25

methanol in dichloromethane to yield 2 (15.2 g) as an off
White Waxy solid.

ester 10. Reaction of 9 With 1 equivalent of ethylbromoacetate
produced the monoester 11.

DTPA Bis-Anhydride, 3.
DTPA (50 g, 0.13 mol) Was added to freshly distilled acetic

anhydride (80 mL) and anhydrous pyridine (80 mL) and

30

anhydrous dioxane (50 mL), and heated to 70° C. under anAr
atmosphere for 7 h. The reaction Was cooled, ?ltered, and the

o

i N/\/ N \/\N ic1:3

35 EtO

OEt

Pentadodecyl Ester of DTPA (C12E5), 8.

—>

0

To a solution of 1-dodecanol (25.0 g, 0.134 mol) in dichlo

l0

romethane (150 mL), triethylamine (21.0 mL, 0.150 mol) and
dimethylaminopyridine (0.5 g) Was added a solution of bro

o

F3C

solid dried under high vacuum at 50° C. to yield the bis

anhydride 3 (35 g) as an off-White poWder. Mp 183-186.

lH-NMR (DMSO-d6) 13.5 (bs, 1H), 3.66 (s, 2H), 3.45 (s,
8H), 3.07 (t, 1:60 HZ, 4H), 2.92 (t, 1:60 HZ, 4H).

OEt

0
40

moacetyl bromide (27.6 g, 0.137 mol) in dichloromethane (50

OEt

mL) at 5° C. dropWise. The mixture Was stirred to room

temperature overnight. The mixture Was ?ltered, Washed With
HN

brine and dried over MgSO4 and the volatiles removed. The

product dodecyl ester Was used Without further puri?cation.
Diethylenetriamine (2.52 g, 0.0244 mol) Was dissolved in

45

/\/ N\/\ NH

EtO

anhydrous acetonitrile (250 mL) and diisopropylethylamine

k'fOEt
O

(21.1 g, 0.742 mol) added. A solution of bromoester 7 (50.0 g,
0.163 mol) in acetonitrile (100 mL) Was added sloWly keep

—>

0
l2
0

ing the internal temperature beloW 15° C. The reaction Was
then alloWed to stir to room temperature overnight. The vola
tiles Were removed and the residue dissolved in ethyl acetate
and Washed With saturated sodium bicarbonate, dried over
NaZSO4 and the solvent removed to an orange oil. Chroma

50

tography on silica gel (5% methanol-chloroform) yielded an
orange oil. MS (MALDI), 1235 (M+1).

55

OEt
N

HOZC

N/\/ \/\N/\CO2H

EtO

OEt

Ditri?uoroacetamide 9.

A solution of diethylenetriamine (20.0 g, 0.194 mol) in

O

O
14

dichloromethane (500 mL) Was cooled to 0° C. and ethyltri
?uoroacetate added dropWise. The reaction Was stirred to
room temperature overnight and then the solvent and volatiles
removed in vacuo to provide a White solid. MS (El) 296

O

60

O

(M+1).
Triethyl ester (C2E3), 10.
The above ditri?uoroacetamide 9 (55 g, 0.186 mol) Was

dissolved in anhydrous DMF (200 mL) and added sloWly at
0° C. to a solution ofNaH (15.6 g, 0.650 mol) in DMF (200

FC
65
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OEt

N

\/\ g

O
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-continued

-continued

0

OEt
N

HZN /\/ \/\ NH2
13
O

OEt

5 R I ethyl
6 R I dodecyl
7 R I octadecyl

HL

20

Tri?uoroacetamides of the type 9 derived from diethylen
etriamine are known to be hydrolyzed in the presence of alkyl
esters, such as benzyl or tert-butyl esters With hydrazine.

Alternatively, the compounds may be hydrolyzed using lim
iting KOH at reduced temperatures. Other possible routes to
the diamino esters derived from 10 and 11 include replacing
the tri?uoroacetamide group With a benzyl urethane Which
can be de-protected non-hydrolytically.
The tri?uoroacetamide groups are removed from 10 and l l

to produce the mono-ethyl and the tri-ethylacetate esters of
diethylenetriamine, l2 and 13. Compounds 12 and 13 my be

O

130% Ph
NH2

R I Phenylalanine Ethyl ester

30

alkylated. The C 12 and C 18 analogs of 12 and 13 are prepared

by the analogous routes. From these, C12El, C12E3, Cl 8E1,
and C18E3 are prepared.

35

In yet another alternative scheme the tri?uoroacetamides
l0, 1 1 may be hydrolyzed using a limiting amount of hydrox
ide at reduced temperatures.

Preparation of the Pentabenzylester 8 and the Pentaamide

o

25

The pentabenzyl ester 8, C benZyZE5 Was prepared as the free
base. The viscous oil Was readily prepared and puri?ed by
column chromatography in multi-gram scale. The pentaa
mide 9, based upon the natural enantiomer of phenylalanine,
Was prepared from phenylalanine ethyl ester in good yield as
a White poWder.

Prodrug Synthesis
40

9

Chemical Synthesis
TWo neW prodrugs Were synthesized and puri?ed. The
chemical characterization of these compounds con?rmed
their structure.

O

HLOH

OH

)1 /\/N\/\
N

O

HO

HO

or

0

in an animal study.
50

0

N

v

yield l4C-DTPA. Both l4C-C2E5 and l4C-DTPA Were used

OH

N

w

)1 /\/N

55

N

OR
60

O
2 R I ethyl
3 R I dodecyl
4 R I octadecyl
8 R I benzyl

The synthesis of the l4C-labeled analog of one of these
prodrugs, C2E5, Was completed and its radiochemical purity
Was con?rmed. A portion of the product Was de-esteri?ed to

H‘OR

OR

R0

45

65

Schematic of Reaction PathWay for:
DTPA Triethyl Ester.
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contained a 10% ethanol to maximize the solubility of the

decorporation agent. The composition of the oral solution

0

formulations is as folloWs:
o

F3C

OEt

o

)L N/\/ N \/\N ic1:3
OEt

—>

C2E5 Oral Solution Formulation 1

EtO

o

Ingredient
o

3

Concentration

C2E5 base
Citric acid

75 mgmL Active
2.10% W/v
Buffer/Solubilizing agent

Methyl paraben

0.18% W/v

Propyl paraben

0.02% W/v

o

Propylene glycol
Sorbitol

3.00% W/v
10.00% W/v

Disodium EDTA
20 Puri?ed Water

q.s. to 100 mL

OEt
N

Function

0.10% W/v

Preservative (Ideal for the pH
range 4-8)
Preservative (Ideal for the pH
range 4-8)
Cosolvent, Preservative aid
SWeetening agent
Anti-oxidant
Vehicle

HN/\/
OEt \/\NH
EtO

o

o

25

C2E5 Oral Solution Formulation 2

4

Ingredient
C2E5 base
Citric acid

N

0.18% W/v

Propyl paraben

0.02% W/v

on

o kyfoiat no? 0
o

Function

75 mgmL Active
2.10% W/v
Buffer/Solubilizing agent

30 Methyl paraben

OEt
HO

Concentration

Propylene glycol
Sorbitol

3.00% W/v
10.00% W/v

Disodium EDTA
Ethanol
Puri?ed Water

0.10% W/v
10.0% W/v
q.s. to 100 mL

Preservative (Ideal for the pH
range 4-8)
Preservative (Ideal for the pH
range 4-8)
Cosolvent, Preservative aid
SWeetening agent
Anti-oxidant
Co-solvent
Vehicle

o

Bioavailability Study

5
40

Using similar technology, the penta-dodecyl DTPA ester
has been prepared.
45

A bioavailability study Was conducted in Which ?ve rats
Were intravenously administered 5 mg of DTPA and another
5 rats Were orally administered an equivalent loWer dose
(approximately 7 mg) of C2E5 in a 10% ethanol solution.
Blood samples Were obtained at regular intervals from an

in-dWelling catheter that had been surgically implanted prior

H

to the administration of the doses. The pharmacokinetic
analysis of the data is presented in FIGS. 1 and 2.
The data indicates that the bioavailability of C2E5 is essen
50

OC12H25
C12H25O

O

O
N

CIZHZSOWH

55

k'(oclzn25

O

gastrointestinal tract it is quantitatively and rapidly converted

OC12H25

fN /\/
O \/\ N

tially 100% in the rat model. Since no C2E5 can be detected
in the plasma, it appears that once C2E5 is absorbed from the

to DTPA. As expected the blood concentration pro?le results
in loWer blood levels and a longer duration compared to IV
DTPA.

Small Animal Decorporation Ef?cacy Study
Studies in small groups of animals have demonstrated that

O

60

6

the decorporation of 241Am folloWing oral administration of
C2E5 to rats compared favorably to decorporation folloWing
IV administration of equivalent doses of DTPA.
The invention has been described herein With regard to

Oral Solution Formulations as Examples of Pharrnaceuti

cal Compositions
TWo oral solution formulations Were developed. The ?rst
formulation Was alcohol free While the second formulation

certain preferred pharmaceutical composition embodiments
65

and treatment methods. HoWever, as obvious variations

thereon become apparent to those skilled in the art, the inven
tion is not to be considered as limited thereto.
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8. The method of claim 5, Wherein said pharmaceutical

What is claimed:

composition also includes a binder.

1. A method of treating a mammal to remove a radioactive

9. The method of claim 5, including using oral administra

element or compound, comprising:
administering to said mammal a pharmaceutically effec

tion.

tive amount of a decorporation agent having a chemical 5
10. The method of claim 5 including administering
formula:
betWeen about 15 and about 45 milligrams of decorporation

agent per kilogram of said mammal’s total body Weight per

day.
O

O

11. The method of claim 5, including administering said
decorporation agent for at least an extended period of time
such as over days and Weeks in order to achieve medically

o %R R)“ o

)k/Nw /\/ NQk

R

N

suf?cient decorporation.
12. A composition for removing a radioactive element or

R

compound from a mammal, comprising:
a pharmaceutical carrier; and
a pharmaceutically effective amount of a decorporation

agent having a chemical formula:

O

Where RihORl or iNHRZ;
RIIsame or different and is independently selected from

20

O

H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or ben
Zyl and at least one R1 is not hydrogen; and
RZIsame or different and is independently selected from

Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or
phenylalanine ethyl ester.

O

O HLR RAIW O

25

RJK/NWN/VNQkR
R

2. The method of claim 1, including using oral administra
tion.

3. The method of claim 1, including administering betWeen
about 5 and about 250 milligrams of decorporation agent per

0
30

kilogram of said mammal’s total body Weight per day.

Where R*\ORl or iNHRZ;

4. The method of claim 3, including administering said
decorporation agent for at least an extended period of time
such as over days and Weeks in order to achieve medically

RIIsame or different and is independently selected from

H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or ben
35

suf?cient decorporation.

Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or
phenylalanine ethyl ester.

5. A method of treating a mammal to remove a radioactive

element or compound, comprising:
administering to said mammal a pharmaceutically effec
tive amount of a pharmaceutical composition including

Zyl and at least one R1 is not hydrogen; and
R2:same or different and is independently selected from

40

a pharmaceutical carrier and a decorporation agent hav
ing a chemical formula:
45

50

R

13. The composition of claim 12, including betWeen about
50 Weight percent and about 98 Weight percent carrier and the
decorporation agent in the carrier at a concentration ranging
from 5 to 250 mg/mL.
14. The composition of claim 13 further including betWeen
about 0.001 and about 3 Weight percent anti-oxidant.
15. The composition of claim 14, Wherein said anti-oxidant
is selected from a group consisting of ascorbic acid, its salts
and esters; fumaric acid, its salts and esters; malic acid, its salt
and esters; alpha-tocopherol, its salts and esters; sodium met

abisulphite, sodium bisul?te; butylated hydroxyanisole
(BHA); butylated hydroxytoluene (BHT); gallic acid, its salts
and esters; EDTA.

16. The composition of claim 13, further including
O
55

Where RihORl or iNHRZ;
RIIsame or different and is independently selected from

ylparaben, propylparaben, butylparaben, benZoic acid,

H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or ben
Zyl and at least one R1 is not hydrogen; and
RZIsame or different and is independently selected from

sodium benZoate, benZyl alcohol, sorbic acid and potassium
60

sorbate, EDTA, glycerol, phenol, thimerosol, phenoxyetha

65

nol, and cresol.
18. The composition of claim 13, further including
betWeen about 0.01 and about 25 Weight percent binder.
19. The composition of claim 18, Wherein said binder is
selected from a group consisting of microcrystalline cellu

Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or
phenylalanine ethyl ester.
6. The method of claim 5, Wherein said pharmaceutical
composition also includes an antioxidant.

7. The method of claim 5, Wherein said pharmaceutical
composition also includes a preservative.

betWeen about 0.001 and about 10 Weight percent preserva
tive.
17. The composition of claim 16, Wherein said preservative
is selected from a group consisting of methylparaben, eth

lose, silicon dioxide, dibasic calcium phosphate, starch, glu
cose, gelatin, acacia, sucrose, dextrin, guar gum, hydroxy

US 8,030,358 B2
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ethyl cellulose, polymethacrylates, maltodextrin, povidone,

400 Monostearate, hydroxy propyl cellulose, hydroxy propyl
methyl cellulose, polyethylene glycol 8000 (PEG 8000), PEG
3350, methyl cellulose, 2-propenoic acid (Carbopol 934P),
polysorbate (TWeen 20), polysorbate 80 (TWeen 80) and
alpha-Tocopheryl polyethylene glycol 1000 succinate

Zein, methyl cellulose, and sodium alginate.
20. The composition of claim 13, further including
between about 0.0001 and about 5.0 Weight percent Viscosity
enhancer.

21. The composition of claim 20, Wherein said Viscosity

(TPGS) and mixtures thereof.

enhancer is selected from a group consisting of beesWaX,

other Waxes, polymer, glycerolmonooleate, lecithin, PEG

*
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*

*

